Evusheld Monoclonal Antibody Treatment
Tixagevimab and cilgavimab (Evusheld) are authorized for patients not currently infected with COVID-19 and who have not been recently exposed. Evusheld is also to be reserved for patients who are moderately to severely immunocompromised who cannot mount an appropriate response to COVID-19 or who cannot be vaccinated due to a history of severe reactions to the vaccine components. This is NOT to be treated as an alternative to vaccination.
Evusheld is being restricted to the following indications:
- Active treatment for solid tumor or hematologic malignancy
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection (people with HIV and CD4 cell counts < 200/mm3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
- Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)
As more supply becomes available, these indications may expand. This website will have the most up-to-date indications and referral form.